<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697226</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-1968-103</org_study_id>
    <nct_id>NCT03697226</nct_id>
  </id_info>
  <brief_title>Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.</brief_title>
  <official_title>An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antiva Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antiva Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical
      precancerous lesions in females without human immunodeficiency virus (HIV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Tolerability of ABI-1968 for the treatment of cHSIL</measure>
    <time_frame>42 days</time_frame>
    <description>Number of Adverse Events related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic exposure to ABI-1968 Topical Cream following topical application to the cervix.</measure>
    <time_frame>42 days</time_frame>
    <description>Plasma concentrations of ABI-1968 over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histopathology of areas with biopsy-proven disease</measure>
    <time_frame>42 days</time_frame>
    <description>Number of subjects with complete and or partial regression of cHSIL by Histopathology</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in HPV viral load following multiple doses of ABI-1968 Topical Cream</measure>
    <time_frame>42 days</time_frame>
    <description>Changes from baseline in HPV viral load following multiple doses of ABI-1968 Topical Cream</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HSIL of Cervix</condition>
  <condition>HSIL, High Grade Squamous Intraepithelial Lesions</condition>
  <condition>High-Grade Cervical Intraepithelial Neoplasia</condition>
  <condition>Human Papilloma Virus</condition>
  <condition>HIV Negative</condition>
  <condition>Cervical Cancer</condition>
  <condition>CIN - Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Neoplasm</condition>
  <condition>Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical ABI-1968</intervention_name>
    <description>Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women, 25 to 50 years old.

          2. Biopsy-confirmed cervical HSIL that is p16+ within 60 days of enrollment (dosing) with
             no evidence of invasive cancer in any specimen.

          3. Colposcopy is satisfactory based on visualization of the entire squamo-columnar
             junction (SCJ). The borders of all lesions must be completely visible.

          4. The upper limit of the visible (usually aceto-white) lesion is within 3 quadrants or
             less at screening.

        Exclusion Criteria:

          1. Women who are pregnant, plan to become pregnant in the next 4 months, or lactating
             females.

          2. HIV positive (tested at screening visit or within 3 months of screening visit).

          3. Resolution of visible CIN lesion prior to enrollment.

          4. ECC positive for glandular disease (adenocarcinoma in situ) or invasive cancer.

          5. History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of
             CIN, or hysterectomy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>650-822-1400</phone>
    <email>clinical@antivabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State Province</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>clinical@antivabio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

